# Ferrer Internacional S.A.

Organization · id `cardio:org-ferrer-internacional-s-a` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=Ferrer+Internacional+S.A.>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: Ferrer Internacional S.A.
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention. (`cardio:ct-nct01321255`)
- Sponsors: Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL Cholesterol (`cardio:ct-nct01362218`)
- Sponsors: Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy (`cardio:ct-nct02791958`)

## Provenance

Content hash: e86252402641e8c5ac67ca0fad96b87731fb4ac9c23ce9b0fa3b90e88d7a57e5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
